Literature DB >> 2893149

Rapid reinfection by Giardia lamblia after treatment in a hyperendemic Third World community.

R H Gilman1, G S Marquis, E Miranda, M Vestegui, H Martinez.   

Abstract

In a peri-urban shanty town in Lima, Peru, that was hyperendemic for Giardia lamblia, 44 children aged between 0.9 months and 10 years were effectively treated for Giardia lamblia with tinidazole. Stools were examined weekly in the 6 months after treatment to determine the rate of reinfection, and after reinfection stools continued to be examined. 98% of the children became reinfected with Giardia lamblia within 6 months, and after reinfection stool excretion of the parasite lasted a mean (SD) of 3.2 (3.3) months. The children's mean stool pH and their mean stool fat index was unaffected by Giardia lamblia reinfection. Treatment of all symptomless Giardia lamblia infections in a developing country hyperendemic for the disease is of questionable value because of rapid reinfection.

Entities:  

Keywords:  Americas; Child Health; Delivery Of Health Care; Demographic Factors; Developed Countries; Developing Countries; Diseases; Health; Health Services; Latin America; Medicine; Parasite Control; Parasitic Diseases--prevention and control; Peru; Population; Population Characteristics; Public Health; Research Report; South America; Urban Population

Mesh:

Substances:

Year:  1988        PMID: 2893149     DOI: 10.1016/s0140-6736(88)91131-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  35 in total

1.  Case-control study of diarrheal disease etiology in a remote rural area in Western Thailand.

Authors:  Ladaporn Bodhidatta; Philip McDaniel; Siriporn Sornsakrin; Apichai Srijan; Oralak Serichantalergs; Carl J Mason
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

2.  Detection of Giardia lamblia antigen in children living in a Peruvian periurban shantytown (Pueblo Joven).

Authors:  M F Vidal; R H Gilman; B L Ungar; M R Verástegui; A C Benel; G Marquis; M Penny; C Lanata; E Miranda
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

Review 3.  Giardiasis: a review on assemblage distribution and epidemiology in India.

Authors:  Shakti Laishram; Gagandeep Kang; Sitara Swarna Rao Ajjampur
Journal:  Indian J Gastroenterol       Date:  2012-02-07

4.  Molecular analysis of household transmission of Giardia lamblia in a region of high endemicity in Peru.

Authors:  Margarethe A Cooper; Charles R Sterling; Robert H Gilman; Vitaliano Cama; Ynes Ortega; Rodney D Adam
Journal:  J Infect Dis       Date:  2010-10-26       Impact factor: 5.226

Review 5.  WITHDRAWN: Drugs for treating giardiasis.

Authors:  J O M Zaat; T H G Mank; W J J Assendelft
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18

Review 6.  Parasitic diarrhoea.

Authors:  R C Mahajan; N K Ganguly; R Sehgal; N Malla
Journal:  Indian J Pediatr       Date:  1988 Nov-Dec       Impact factor: 1.967

7.  Lack of an adverse effect of Giardia intestinalis infection on the health of Peruvian children.

Authors:  Maria-Graciela Hollm-Delgado; Robert H Gilman; Caryn Bern; Lilia Cabrera; Charles R Sterling; Robert E Black; William Checkley
Journal:  Am J Epidemiol       Date:  2008-07-31       Impact factor: 4.897

8.  Resistance to reinfection in mice as a vaccine model for giardiasis.

Authors:  Erqiu Li; Mingqiu Liu; Steven M Singer
Journal:  Hum Vaccin Immunother       Date:  2014-05-07       Impact factor: 3.452

9.  Draft genome sequencing of giardia intestinalis assemblage B isolate GS: is human giardiasis caused by two different species?

Authors:  Oscar Franzén; Jon Jerlström-Hultqvist; Elsie Castro; Ellen Sherwood; Johan Ankarklev; David S Reiner; Daniel Palm; Jan O Andersson; Björn Andersson; Staffan G Svärd
Journal:  PLoS Pathog       Date:  2009-08-21       Impact factor: 6.823

10.  Severity of Giardia infection associated with post-infectious fatigue and abdominal symptoms two years after.

Authors:  Kristine Mørch; Kurt Hanevik; Guri Rortveit; Knut-Arne Wensaas; Geir Egil Eide; Trygve Hausken; Nina Langeland
Journal:  BMC Infect Dis       Date:  2009-12-15       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.